Sonal Bhatia, MDChief Medical Officer, Rare Diseases at Pfizer Inc.
Sonal Bhatia is Chief Medical Officer for Rare Disease. Her patient centric mindset and drive to engage key stakeholders externally motivates her to elevate the voice of medical and lead the organization to become the “trusted partner and demonstrated leader in the rare disease community” we aspire to be in our Rare Disease BU strategic plan.
Prior to this role, Sonal held the position of VP, North America Medical Affairs Lead for Rare Disease. In this role, Sonal played a key part in the successful launch of Tafamidis, which is still ongoing worldwide for Rare Disease. She also has experience preparing the healthcare marketplace for innovative solutions for the delivery of medicines to patients, which will be critical to our future gene therapy pipeline. In addition, Sonal also previously served as Senior Medical Director & Team Lead, for Eliquis, bring about a new era of Real-World Evidence generation for physicians.
Sonal was recognized with the 2018 Rising Star Award by the Healthcare Businesswomen’s Association (HBA).
Sonal is actively involved with non-profit organizations focused on reducing disparities for access to cardiovascular health and healthy living and being catalyst for change for women’s health. She currently serves on the Board of Directors for the American Heart Association (AHA) and is on the Executive Leadership for AHA Go Red for Women. She is a speaker at various panels and conferences internationally, driving the future of Medical Affairs.